CROs and contract manufacturers had a decent second quarter, but they are hoping that Big Pharma comes through with a burst of trial start-ups in the second half of 2003.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.